Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is an incurable lung disease with a poor prognosis. Fibroblasts and myofibroblasts are the key cells in the fibrotic process. Recently two drugs, pirfenidone and nintedanib, were approved for clinical use as they are able to slow down the disease progression. The mechanisms by which these two drugs act in in vitro cell systems are not known. The aim of this study was therefore to examine the effects of pirfenidone and nintedanib on fibroblasts and myofibroblasts structure and function established from patients with or without IPF. METHODS: Stromal cells were collected and cultured from control lung (n = 4) or IPF (n = 7). The cells were treated with pirfenidone and/or nintedanib and the effect of treatment was evaluated by measuring cell proliferation, alpha smooth muscle actin (α-SMA) and fibronectin expression by Western analysis and/or immunoelectron microscopy, ultrastructural properties by transmission electron microscopy and functional properties by collagen gel contraction and invasion assays. RESULTS: Both pirfenidone and nintedanib reduced in vitro proliferation of fibroblastic cells in a dose dependent manner. The number of cells from control lung was reduced to 47 % (p = 0.04) and of IPF cells to 42 % (p = 0.04) by 1 mM pirfenidone and correspondingly to 67 % (p = 0.04) and 68 % (p = 0.04), by 1 μM nintedanib. If both drugs were used together, a further reduced proliferation was observed. Both pirfenidone and nintedanib were able to reduce the amount of α-SMA and the myofibroblastic appearance although the level of reduction was cell line dependent. In functional assays, the effect of both drugs was also variable. CONCLUSIONS: We conclude that the ultrastructure and function of fibroblasts and myofibroblasts are affected by pirfenidone and nintedanib. Combination of the drugs reduced cell proliferation more than either of them individually. Human lung derived cell culture systems represent a potential platform for screening and testing drugs for fibrotic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, this compound reduces fibroblast proliferation and attenuates TGFβ-induced αSMA and collagen production in primary skin fibroblast (192, 193).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [193]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Prednisone, Azathioprine, and N -Acetylcysteine for Pulmonary Fibrosis
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113354 · Cited by 1,621
Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction
Gabbiani, G., Ryan, G. B., & Majno, G. (1971) · Experientia · doi:10.1007/bf02147594 · Cited by 1,485 · cited 1×
“Originally myofibroblasts were discovered during EM investigations of a healing wound [21].”
Rock, J. R., Barkauskas, C. E., Cronce, M. J., Xue, Y., Harris, J. R., Liang, J., Noble, P. W., & Hogan, B. L. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117988108 · Cited by 1,030 · cited 1×
“In particular, we and other investigators have observed that fibroblasts and myofibroblasts containing cells lines cultured from IPF patients are more invasive than the cells obtained from other lung diseases [11, 13].”
Moeller, A., Ask, K., Warburton, D., Gauldie, J., & Kolb, M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.08.011 · Cited by 1,007 · cited 1×
“For instance, bleomycin-induced fibrosis in rodents resembles rather poorly the IPF in humans [16, 17], and further, the pulmonary anatomy and cellular components of rodents and other experimental animals are very different from their human counterparts.”
Wollin, L., Maillet, I., Quesniaux, V., Holweg, A., & Ryffel, B. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.208223 · Cited by 633 · cited 2×
“In lung tissue of mice, nintedanib reduced total lung collagen levels, as well as the extent of inflammation and fibrosis and prevented granuloma formation [30].”
Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401739 · Cited by 505
(2007) · Clinical Atlas of Interstitial Lung Disease · doi:10.1007/978-1-84628-326-0_6 · Cited by 499
Kuhn, C., & McDonald, J. A. (1991) · PubMed · Cited by 472
Cited by
Interstitial lung disease associated with systemic sclerosis (SSc-ILD)
Cottin, V., & Brown, K. K. (2019) · Respiratory Research · doi:10.1186/s12931-019-0980-7 · Cited by 292
Finnerty, J. P., Ponnuswamy, A., Dutta, P., Abdelaziz, A., & Kamil, H. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01783-1 · Cited by 209
“Their modes of action are not completely understood but there is evidence of considerable overlap [5, 6], and they have similar effects in clinical practice.”
BackgroundA Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly
Knüppel, L., Ishikawa, Y., Aichler, M., Heinzelmann, K., Hatz, R., Behr, J., Walch, A., Bächinger, H. P., Eickelberg, O., & Staab-Weijnitz, C. A. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0217oc · Cited by 183
Unraveling SSc Pathophysiology; The Myofibroblast
van Caam, A., Vonk, M., van den Hoogen, F., van Lent, P., & van der Kraan, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02452 · Cited by 153
Nathan, S. D., Waxman, A., Rajagopal, S., Case, A., Johri, S., DuBrock, H., De La Zerda, D. J., Sahay, S., King, C., Melendres-Groves, L., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00165-x · Cited by 152
Metadata
- Authors
- Lehtonen, S. T., Veijola, A., Karvonen, H., Lappi-Blanco, E., Sormunen, R., Korpela, S., Zagai, U., Sköld, M. C., & Kaarteenaho, R.
- Affiliations
- Oulu University Hospital (FI)
- University of Toronto (CA)
- Karolinska Institutet (SE)
- University of Eastern Finland (FI)
- Corresponding author
- Lehtonen, Siri T.
- Venue
- Respiratory Research
- Published
- 2016-02-04
- Volume
- 17
- Issue
- 1
- Pages
- 14-14
- ISSN
- 1465-9921 (ISSN-L)
- 1465-993X
- PMC
- PMC4743320
- OpenAlex
- W2267777024
- Cited by
- 133
- References
- 35
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 4 · 2023: 11 · 2022: 15 · 2021: 20 · 2020: 7 · 2019: 15 · 2018: 22 · 2017: 19 · 2016: 5
- FWCI
- 18.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Respiratory Research (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- TSpace (University of Toronto) (submittedVersion)
- Funders
- Foundation of the Finnish Anti-Tuberculosis Association
- Jalmari and Rauha Ahokas Foundation
- Väinö and Laina Kivi Foundation
- Swedish-Finnish Cultural Foundation
- Oulu University Hospital
- Hjärt-Lungfonden
- Otto A. Malm Foundation
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- idiopathic pulmonary fibrosis, pirfenidone, nintedanib, fibroblasts, myofibroblasts, fibroblast proliferation, alpha-smooth muscle actin, fibronectin, collagen gel contraction, cell invasion, combination therapy, antifibrotic agents, drug screening
- MeSH terms
- Anti-Inflammatory Agents, Non-Steroidal, Cells, Cultured, Dose-Response Relationship, Drug, Drug Therapy, Combination, Fibroblasts, Humans, Indoles, Pyridones, Treatment Outcome, Cell Proliferation, Idiopathic Pulmonary Fibrosis, Myofibroblasts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1186/s12931-016-0328-5
- The paper
- Lehtonen, S. T., Veijola, A., Karvonen, H., Lappi-Blanco, E., Sormunen, R., Korpela, S., Zagai, U., Sköld, M. C., & Kaarteenaho, R. (2016). Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. Respiratory Research. https://doi.org/10.1186/s12931-016-0328-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.